122 related articles for article (PubMed ID: 35930797)
1. New-Onset Myasthenia Gravis Confirmed by Electrodiagnostic Studies After a Third Dose of SARS-CoV-2 mRNA-1273 Vaccine.
Slavin E; Fitzig J; Neubert C; Garcia-Lopez F; Cuevas-Trisan R
Am J Phys Med Rehabil; 2022 Dec; 101(12):e176-e179. PubMed ID: 35930797
[TBL] [Abstract][Full Text] [Related]
2. Letter to the Editor on "New-Onset Myasthenia Gravis Confirmed by Electrodiagnostic Studies After a Third Dose of SARS-CoV-2 mRNA-1273 Vaccine".
Kim S; Eun MY; Seok HY
Am J Phys Med Rehabil; 2023 Jul; 102(7):e102. PubMed ID: 36762834
[No Abstract] [Full Text] [Related]
3. New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series.
Fanella G; Baiata C; Candeloro E; Toscano G; Colnaghi S; Mauri M; Cariddi LP; Rebecchi V; Solazzo F; Banfi P; Piatti M; Ferrarese C; Versino M
Neurol Sci; 2022 Oct; 43(10):5799-5802. PubMed ID: 35870026
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience.
Farina A; Falso S; Cornacchini S; Spagni G; Monte G; Mariottini A; Massacesi L; Barilaro A; Evoli A; Damato V
Eur J Neurol; 2022 Aug; 29(8):2505-2510. PubMed ID: 35390184
[TBL] [Abstract][Full Text] [Related]
5. A Case of COVID-19 Vaccine Associated New Diagnosis Myasthenia Gravis.
Chavez A; Pougnier C
J Prim Care Community Health; 2021; 12():21501327211051933. PubMed ID: 34709075
[TBL] [Abstract][Full Text] [Related]
6. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees.
Jacobson MA; Zakaria A; Maung Z; Hart C; McCalmont TH; Fassett M; Amerson E
Clin Infect Dis; 2022 Mar; 74(4):591-596. PubMed ID: 34086881
[TBL] [Abstract][Full Text] [Related]
7. Myasthenia Gravis Presenting after Administration of the mRNA-1273 Vaccine.
Hoshina Y; Sowers C; Baker V
Eur J Case Rep Intern Med; 2022; 9(7):003439. PubMed ID: 36051160
[TBL] [Abstract][Full Text] [Related]
8. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021.
Tenforde MW; Patel MM; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Botros M; Lauring AS; Shapiro NI; Halasa N; Chappell JD; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Rhoads JP; Lindsell CJ; Hart KW; Zhu Y; Naioti EA; Adams K; Lewis NM; Surie D; McMorrow ML; Self WH;
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):118-124. PubMed ID: 35085218
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 Vaccination and Late-Onset Myasthenia Gravis: A New Case Report and Review of the Literature.
Virgilio E; Tondo G; Montabone C; Comi C
Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612789
[TBL] [Abstract][Full Text] [Related]
11. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
12. Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Galassi G; Rispoli V; Iori E; Ariatti A; Marchioni A
Isr Med Assoc J; 2022 Jan; 24(1):9-10. PubMed ID: 35077038
[TBL] [Abstract][Full Text] [Related]
13. Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis.
Reyes-Leiva D; López-Contreras J; Moga E; Pla-Juncà F; Lynton-Pons E; Rojas-Garcia R; Turon-Sans J; Querol L; Olive M; Álvarez-Velasco R; Caballero-Ávila M; Carbayo Á; Vesperinas-Castro A; Domingo P; Illa I; Gallardo E; Cortés-Vicente E
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35728947
[TBL] [Abstract][Full Text] [Related]
14. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years - United States, August 31-October 23, 2022.
Hause AM; Marquez P; Zhang B; Myers TR; Gee J; Su JR; Blanc PG; Thomas A; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(44):1401-1406. PubMed ID: 36327162
[TBL] [Abstract][Full Text] [Related]
15. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
17. New-onset Myasthenia Gravis after SARS-CoV-2 infection: case report and literature review.
Tereshko Y; Gigli GL; Pez S; De Pellegrin A; Valente M
J Neurol; 2023 Feb; 270(2):601-609. PubMed ID: 36352330
[TBL] [Abstract][Full Text] [Related]
18. Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients.
Sansone G; Bonifati DM
J Neurol; 2022 Aug; 269(8):3965-3981. PubMed ID: 35503373
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era.
Ioannou GN; Bohnert ASB; O'Hare AM; Boyko EJ; Maciejewski ML; Smith VA; Bowling CB; Viglianti E; Iwashyna TJ; Hynes DM; Berry K;
Ann Intern Med; 2022 Dec; 175(12):1693-1706. PubMed ID: 36215715
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 vaccination and new-onset myasthenia gravis: A report of 7 cases and review of the literature.
Ramdas S; Hum RM; Price A; Paul A; Bland J; Burke G; Farrugia M; Palace J; Storrie A; Ho P; Standing E; Lilleker JB; Jungbluth H
Neuromuscul Disord; 2022 Oct; 32(10):785-789. PubMed ID: 36130855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
